Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.00    0.25 (0.97%)
Bid:
25.50
Ask:
26.50
Spread: 1.00 (3.922%)
Market Cap: £130.91m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading Update

4 Feb 2021 07:00

RNS Number : 9284N
Duke Royalty Limited
04 February 2021
 

4 February 2021

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to provide the following trading and operational update for its third financial quarter ended 31 December 2020 ("Q3 FY21") and to provide guidance on trading for its fourth financial quarter ending 31 March 2021 ("Q4 FY21").

Highlights:

· Cash revenue for Q3 FY21, being cash distributions from Duke's Royalty Partners and cash gains from sales of equity assets, totalled £4.2m which represents a record quarter of cash revenue generation for Duke.

· Within the £4.2m of quarterly cash revenue, £1.7m related to the receipt of the redemption premium generated from the exit of Welltel, which occurred in December 2020. Once this positive effect is stripped out, like for like cash revenue for Q3 FY21 stood at £2.5m. This is in line with management's expectations and represents an increase from the £2.4m reported in Q2 FY21 and £2.0m in Q1 FY21.

· An IRR of 27% was generated from Duke's investment in Welltel. This was the Company's largest investment and represented the second exit of a royalty partner, further validating the Duke investment model.

· Based on current trading, Duke expects cash revenue for Q4 FY21 to be £2.5m, despite Welltel contributing no cash revenue in the quarter. Prior to exit, Welltel was delivering quarterly cash revenue of £450,000, highlighting the ongoing improvement in the cash generation of the existing portfolio.

 

· Duke also announced two separate follow-on transactions in December which included investments into MRDB Holdings Limited and BHPC Limited.

· As a result of the Welltel exit, the two new deployments in Q3 FY21 and the Step Investments deployment that closed in early January 2021, net debt currently stands at £5.6m, significantly below the £14.0m announced on 12 November 2020. This provides Duke with considerable liquidity for new investments.

· On 12 January 2021 Duke announced the appointment of Peter Madouros as Group Chief Investment Officer ("CIO"), in line with its planned succession strategy whereby Jim Webster, Duke's current CIO, will take up the role of Chairman of the Investment Committee. Duke is delighted to have Peter join the investment team while also retaining Jim's experience during both the due-diligence and deal execution process.

· Duke's pipeline remains strong and management is confident of being able to announce additional follow-on as well as new deployments in the near future, in line with market expectations.

Neil Johnson, CEO of Duke Royalty, said:

"I am pleased to report that cash revenue has continued to increase in Q3 FY21 in comparison to Q2 FY21, testament to the resiliency of our portfolio. In the quarter, Duke achieved one major exit and made two follow-on investments, while also expanding the investment team through the appointment of Peter Madouros as CIO.

"While the macro environment remains highly volatile, the pandemic has also presented Duke with a significant growth opportunity. Banks have been tightening SME lending criteria ever since the global financial crisis and demand for more flexible, alternative sources of capital remains very strong. As a first mover and leader in the UK and European corporate royalty space, Duke has a significant opportunity to build and further diversify its portfolio. Importantly, we have significant liquidity available for new deployments, which adds to our high level of confidence as we enter 2021."

 

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell/ Tom Carnegie/ Megan Kovach

+ +44 (0) 20 3757 6880 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVDFAIVIIL
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.